Historial de carrera de Richard Chesworth
Antiguos cargos conocidos de Richard Chesworth.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| KYMERA THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 27/08/2020 | 22/10/2021 |
| EPIZYME, INC. | Director Técnico/Científico/I+D | - | - |
Formación de Richard Chesworth.
| Imperial College London | Undergraduate Degree |
| University of Oxford | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 3 |
| Reino Unido | 3 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Richard Chesworth
- Experiencia